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Clinical decision ma 
cQ~~e~~§ a 
lem solving. Eva~wa~~Q~ of patient nosis is a critical 
A clinician makes hundreds of decisions every day, some individual c inicians must justify their therapeutic choices to 
mundane, others concerning matters of life and death. The review panels and third party payers. The profession itself 
sum of these decisions by the half-million phy- must demonstrate that tecbno~og~cally sophisti- 
sicians in the United States profoundly affects cated and expensive modes of therapy are 
the health of the country and controls the bulk of worthwhile. Clinical decision making is under 
medical care costs (I)--$500 billion in 1987 (2). * - scrutiny, and pressures are rising to improve 
Because cardiovascular disease is the leading : . both the process by which clinical decisions arc 
cause of death and a major cause of morbidity. . made and the data on which they are based. 
disability and health care costs (3), the decisions This article reviews elected aspects of the 
made by cardiovascular specialists have partic- process of clinical decision making. First, we 
ular significance. A N N ’ ” E R s A R y discuss how physicians make decisions. Next, 
Clinicians once made decisions with virtual ’ ’ 4 ’ _ ’ ’ 8 ’ we review the methods of prognostic stratifica- 
autonomy, but that freedom is eroding quickly. Increasingly. (ion, with emphasis on the use of the Cox proportional 
hazards model. We then examine the relative strengths of
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use of randomized trials and observational analyses. Finally, 
we outline some future trends for clinical trials, meta nal- 
ysis and data base research. 
Clinical Decision M 
in principle, physicians hould use the linear, logical 
reasoning processes xemplified bydecision analysis (45) to 
make therapeutic recommendations. First, the patient’s di- 
,agnosis and underlying prognosis are established accurately. 
Second, the possible therapeutic alternatives are identified, 
and the effect of each alternative on patient OUtCOme is 
estimated. Not only is the effect on survival assessed, but 
also many additional factors are taken into account, such as 
the effect on quality of life, functional capacity, employment 
status, medical costs and the patient’s values and prefer- 
ences. Finally, the benefits, risks and costs of each altema- 
tive are weighed, and the best course of action is under- 
taken. 
Although this process is highly rational, clinicians do not 
usually make decisions in this fashion (6). Instead, experts in 
a variety of fields make decisions using a more intuitive 
process of recognizing patterns and applying heuristics 
(rules of thumb) (7-9). In cardiovascular medicine, for 
instance, a rule of thumb might be that “patients with 
sigaificant left main coronary artery disease should have 
coronary bypass urgery.” This particular heuristic is gen- 
erally accepted, but many of the rules of thumb used by 
individual clinicians are more personal and idiosyncratic. 
‘Ihe process by which new data re absorbed and formulated 
iuto heuristics remains poorly understood. In varying pro- 
f*rtions, pathophysiologic reasoning, personal c inical expe- 
rience, published research and the opinion of experts in the 
field each play a role in the development of clinical rules of 
thumb. 
Selection f therapy. This depends critically on an under- 
lying model of the disease process, because the pathophys- 
iology of disease often suggests a method for its treatment. 
Antibiotic therapy for endocarditis is rational, based on the 
current concepts of bacterial pathogenesis and specific ex- 
perimental models of endocarditis. Coronary angioplasty has 
been widely used, in large part because of the perception 
that it corrects the immediate cause of myocardial ischemia. 
Nonetheless, knowledge of pathophysioiogy is far from 
complete and, for some disorders, it may be rudimentary. 
Advances in pathophysiologic understanding may suggest 
new approaches to therapy or, alternatively, may undermine 
the rationale for previously accepted techniques (e.g., peri- 
cardial poudrage for the treatment of coronary artery disease 
or prolonged bed rest after myocardial i$arctiott). 
In addition to pathophysiologic reasoning, physicians 
APPLY their personal experience and information from clini- 
cal research to arrive at therapeutic recommendations. The
physician’s recall of personal clinical experience is noto+ 
ously selective, however, being too heavily influenced by 
recent cases or particularly bad or good outcomes (IO). 
Computerized clinical data bases were developed inpart to 
overcome these recognized deficiencies in human memory 
by providing a complete and unbiased picture of clinical 
experience. Clinical research reports hould be the soundest 
basis for therapeutic decisions, because they aim to evaiuate 
the efficacy of therapy directly. However, the quality of this 
evidence varies among studies, and much of it is open to 
several interpretations. Although forums such as the Na- 
tional Institutes of Health Consensus Development Confer- 
ences may foster more uniform therapeutic recommenda- 
tions, legitimate differences ofopinion about proper clinical 
management are likely to remain (10). 
Variability in physician de&ion making. Such variability 
is evident from recent studies documenting substantial geo- 
graphic differences in the use of various cardiac procedures. 
Coronary artery bypass graft surgery has one of the highest 
rates of variation of any surgical procedure (1 I). One study 
among Medicare beneficiaries (11) found the rate of bypass 
surgery in different areas of the United States varied three- 
fold, from a low of 7110,000 to a high of 23110,000. The use of 
cardiac atheterization also showed substantial variation, 
from a low of 22110,000 to a high of 51/10,000 Medicare 
beneficiaries (12). Wennberg and coworkers (13) compared 
hospitalization rates for a variety of diagnoses in the cities of 
Boston and New Haven. These investigators found that the 
rate of hospital admission for atherosclerosis and coronary 
bypass surgery varied twofold between these two cities, 
although the rate of admission for acute myocardial infarc- 
tion varied only slightly. One important difference among 
these conditions i  that widespread consensus exists that 
patients with acute myocardial infarction should be admitted 
to the hospital, but there is far less consensus about when 
patients need to be admitted for treatment ofchronic oro- 
nary disease or for bypass surgery. “Black and white” 
decisions exhibit little variability among physicians, al- 
though “gray zone” decisions are highly variable. 
Variability in decision making has attracted the attenau 
of health care policy makers and those concerned about high 
medical costs. It will be increasingly important for the 
cardiovascular specialists oattempt to define the appropri- 
ate indications for procedures, and to base these recommen- 
dations on data from clinical research studies whenever 
possible. 
Therapeutic decision making requires an appreciation f 
the prognosis of disease and methods of risk ~tratihcation, 
because therapeutic recon,.mendations should be quite dif- 
ferent for a patient with a good prclgnosis than for a patient 
with a very poor prognosis. Outcomes are not uniform even 
in a group of patients with the same disease: some patients 
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the 1 year survival 
advantages of this statistic are that it su 
myocardial infarction and I1 months after myocardi~ infarc- 
tion are considered equivalently, although a patient who died 
13 months afterward would be considered alive for the 
purposes of calculating 1 year survival rate. Further- 
more, a patient who was wn to be alive at 8 rno~tb~ after 
myocardiai infarction would not be included at all, because 
he had not been follo up for the required I year. 
technique of Kaplan- r life table analysis everco 
these limitations (14-16). In the construction ofa life table, 
each patient contributes information from the time o 
entry until either the time of death or last follow-up contact. 
This information isthen combined using special techniques 
to estimate the probability of a patient’s being alive at any 
point in time after study entry. This powerful technique 
includes observations from ail patients regardless of their 
length of follow-up. This information is often presented 
graphically inthe form of a survival curve that displays the 
likelihood of survival at any time point rather than only at a 
single arbitrary point in time. More detailed escriptions of
life table methods can be found in standard statistics refer- 
ences (14-16). 
Evaluation of survival curves. One important assumption 
in the use of survival rates is that the underlying probability 
of death for all patients in the cohort is the same. In fact, 
prognosis i  generally affected by a large number of factors 
including the patient’s age, gender, symptom severity, ex- 
tent of disease and coexisting medical disorders. Conse- 
quently, techniques are needed to identify prognostic fac- 
tors, quantify their strength and assess their relative 
importance. These techniques must handle variable lengths 
of patient follow-up and provide stimates ofsurvival prob- 
ability that apply to individual patients. If the shapes of 
wn or reaso 
patient i at time t (hi(t)) e 
“average patient” at the 
e lasta~taaeous 
i(t) = h(t) Ci, where Ci 
zard (h) of death for 
the hazard of death for an 
time (h(t)) multiplied by a 
) that measure the strengt 
prognostic factor and outcome. Thzse coeffi- 
cients must be estimated from observations of the outcomes 
bers of patients with the same disorder. 
This is the major use of the Cox proportional hazards model. 
A number of computer programs perform the necessary 
calculations simply and easily (18,19). The ready availability 
of such statistical software packages has allowed many 
researchers to use the Cox model without necessarily appre- 
ciating its assumptions and limitations. For instance, the 
strength of a prognostic factor may be greater during one 
period of time than another. A prominent example of such a 
factor is surgical therapy, which entails a short-term risk of 
operative mortality, yet offers long-term benefit n terms of 
survival. In comparing a therapy such as surgery with 
another therapy that is not associated with a period of early 
high risk, a standard Cox model must be used with consid- 
erable caution, because the survival curves have different 
shapes and the proportional hazards assumption is violated 
(10). 
The Cox model also assumes that he effect of a prognos- 
tic factor on outcome is linear. The validity of this assump- 
tion should be checked in the analysis. For example, left 
ventricular ejection fraction is a strong prognostic factor 
among patients with coronary artery disease. An ejection 
fraction >60%, however, is not associated with any lower 
hazard of death than that of an ejection fraction of 60% (20). 
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In the model, therefore, the value of ejection fraction should 
be truncated at 60% to indicate its effect on prOgnOSis 
accurately. 
Importance of statistical power and type II error in inter- 
p,-ebtio~~ of do&ed trials. These factors are now widely 
appreciated (21). The concept of statistical power is less 
frequently applied to prognostic studies, but remains just as 
relevant. In survival analyses, the statistical power for 
detecting a prognostic factor is determined chiefly by the 
number of outcome vents, not by the total number of 
patients. For example, a study with 100 patients and 25 
deaths has greater statistical power for analysis Of prognosis 
than does a second study with 500 patients and 10 deaths, all 
other aspects of the studies being equal. In attempting to
increase the number of outcome vents, some clinical stud- 
ies combine diverse end points such as death, nonfatal 
myocardial infarction and coronary bypass urgery. Such 
compound end points can be very useful for comparing 
different therapies when they are used to summarize the 
proportion of patients with a predefined “poor outcome.” 
However, compound end points hould be interpreted with 
great caution in prognostic studies, because the mechanisms 
and risk factors for the individual outcomes are likely to be 
quite different. For instance, an analysis of 50 events con- 
sisting of 4 deaths, 10 nonfatal myocardial infarctions and 36 
surgical procedures will primarily identify the factors clini- 
cians use to select patients for surgery, not the determinants 
of the “natural history” of disease. 
Another important aspect of prognostic analysis is the 
problem of a “false positive,” i.e., identifying a factor as a 
significant predictor of prognosis that has no real effect on 
outcome (type I error). This problem is particularly acute 
when more than one potential prognostic factor is analyzed 
per 10 outcome vents in the sample (22). For instance, a
study with 30 outcome vents can alford examination f only 
three candidate prognostic factors. If a larger number of 
factors were analyzed, the likelihood of spurious associa- 
tions would be increased. 
Clinical indexes as prognostic factors. Regression model- 
ing techniques for prognostic analysis can be enhanced by 
the use of clinical indexes (22) that combine several clinical 
variables measuring different aspects of the same underlying 
pathophysiologic phenomenon. For instance, the presence 
of cardiomegaly, an S3 gallop, a history of myocardial 
infarction and Q waves on the ECG all measure different 
aspects of the extent of myocardial damage. The lidI impor- 
tance of myocardial damage as a prognostic factor might be 
overlooked by placing each of these variables separately in a 
StePwiSe WWssion analysis, particularly if there are rela- 
tively few outcome vents. A clinical index that combines 
the information provided from several related variables i a 
more powerful Prognostic factor than any individual vat+ 
able; it improves the reproducibility of the prognostic model 
Table 1. Clinical Research Designs in Increasing Order of Rigor 
NQ controls (case reports, case series) 
Literature controls 
Historical controls 
Concurrent controls 
Concurrent controls with multivariable analysis 
Randomized controlled trial 
and more closely simulates the clinician’s “gestalt” impres- 
sion of the patient’s illness (22). 
Variables of prognostic importance may be discrete (e.g., 
male, female) or they may be continuous (e.g., ejection 
fraction). Many studies analyze the strength of a continuous 
prognostic factor by setting an arbitrary “cut point” and 
dividing the patients into subgroups with values above and 
below the cut point. Although this technique is helpful to 
illustrate findings and to facilitate drawing survival curves, it 
discards valuable prognostic information and may weaken 
the apparent prognostic significance of a continuous vari- 
able. For instance, the ejection fraction is often described as 
being above or below 40%. It is important to recognize that 
dividing patients in this fashion above and below 40% 
implicitly assumes that an ejection fraction of 39% has the 
same prognostic mportance as an ejection fraction of 12%. 
The value of ejection fraction as a prognostic factor would be 
considerably underestimated by an analysis that lumps to- 
gether patients with such markedly different prognoses. 
hicar t?St?24t-t! 
While pathophysiologic insight may be necessary for the 
development of medical therapeutics, empiric testing re- 
mains essential. The history of medicine isfilled with exam- 
ples of seemingly rational therapies that have failed the 
empirical test. In 1989, for instance, the hypothesis that 
antiarrhythmic drug therapy after myocardial infarction 
would reduce sudden death was forcefully rejected by the 
observation that flecainide and encainide actually increa.sed 
sudden death (23,23a). The hypothesis that coronary angio- 
plasty perfo,med immediately after thrombolysis for acute 
myocardial infarction would improve outcome has been 
tested in three randomized controlled clinical trials (24-27) 
without evidence for efficacy. The failure of a seemingly 
rational therapy to work as planned leads to refinement of
the initial hypothesis and, it is hoped, to improvement of the 
underlying pathophysiologic model. Such failures dramati- 
cally illustrate the need for rigorous empiric testing of 
therapeutic hypotheses. 
Clinical research designs (Table 1). Clinical research re- 
garding therapies may be classified within a hierarchy of 
increasing rigor. Clinical observations such as case reports 
and case series are the least rigorous design. However, 
virtually all therapeutic innovations begin with the report of 
a few cases. The power of a key observation may be 
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cient to alter an entire para for trcatme~t. because 
kes only a few cases to de trate the potential of a 
new technique. Electrical de~bril~atio~, angi 
valv~~op~asty were remarkable advances that 
tirely new eras of treatment by demonstrating powerful 
therapeutic principles. Altbo~gh a ional studies of more 
stringent design are generally flee to measure the effec- 
tiveness of a novel tberap;l act ly and to test it in 
relation to standard therapy, most innovations are first 
reported as uncontrolled observations (28). 
The degree of rigor in clinical research design depends, in
large part, on the quality of the control group i 
most accessible standard of comparison is
experience of other institutions with treatme 
with the same illness. However, because institutions 
disease incidence and severity, referral patterns. t 
of diagnosis, ancillary therapy and selection of patients for 
rapies, controls from published studies are not 
trois of previously treated patients 
from the same i~stitutioo are an improvement over controls 
from published studies, because variability insome of these 
factors is eliminated. Nevertheless, changes inpatient selec- 
tion and supportive care can lead to better outcomes inmore 
recently treated patients. A few diseases, however. have 
suck a uniform and predictable clinical course that use of 
controls from published reports or historical controls may be 
sufficient. Ventricular fibrillation and infective ndocarditis 
were essentially 100% fatal before the introduction ofelec- 
trical defibrillation and antibiotics, respectively. Given the 
uniformly dismal prognosis, the effect of potential confound- 
ing factors was not an issue, so that he striking effects of the 
new therapy were obvious. There are very few conditions 
today for which either controls from published ata or 
historical controls would be adequate. 
Concurrent controls from the same institution assure 
greater comparability of patients than do historic ontrols. 
because patient referral patterns and supportive care are 
similar. A concurrent control group may differ from treated 
patitnts in other ways, however. In particular, low risk 
patients may be selected for the new therapy, although the 
high risk patients might receive the older control therapy. 
This problem can be partially alleviated through the use of 
multivariable analysis to correct for imbalances in prognos- 
tic factors between treatment groups, as discussed indetail 
in a later section of this report. Assignment of therapy 
randomly, as is done in a randomized controlled clinical 
trial, represents he ultimate method of assuring that patient 
groups are comparable for all other factors except hat of 
treatment. 
The prospective randomized controlled clinical trial rep- 
resents a major development in the evaluation of medical 
r Randomized Clinical Trials in 
Lipid Research Clinics Primary Prevention Trial (30.3 I) 
Multiple Risk Factor intervention Trial (32) 
Physicians’ Health Study (33) 
Helsinki Heart Study (34) 
Oslo Study of Diet and Smoking Intervention (3.5) 
ypertension 
Veterans Administration Cooperative Study (36.37) 
United States Public Health Service Trial (38) 
Hypertension Detection and Follow-up Program (39-42) 
Austrahan Trial (43.44) 
Medical Research Council Trial (45) 
Coronary artery bypass surgery 
Veterans Administration Cooperative Study (46-49) 
European Coronary Surgery Study (50-52) 
Coronary Artery Surgery Study (53-55) 
National Cooperative Unstable Angina Study (56.57) 
Thromholysis fw acute myocardial infarction 
Thrombolysis in Myocardial infarction Study. Phase I (58-60) 
Gruppo ltaliano per lo Studio della Streptochinasi nell’ Infarct0 
Miocardico GISSI) (61) 
Second international Study of Infarct Survival WS-2) (62) 
European Cooperative Studies (63-65) 
Congestive heart failure 
Cooperative North Scandinavian Enalapril Survival Study (66) 
Veterans Administration Study of Vasodilator Therapy (67) 
Secondary prevention after myacardiai infarction 
Coronary Drug Project (68.69) 
Beta-Blocker theart Attack Trial (70-72) 
Aspirin Myocardial infarction Study (73) 
Multicenter Diltiazem Postinfarction Trial 174) 
Persantine-Aspirin Reinfarction Study (7% 
Unstable angina 
Canadian Muhicenter Study 1761 
Veterans Administration Study (q7) 
Montreal Study (781 
therapeutics. This study design was initially used by the 
father of modern statistics, R. A. Fisher, in agricultural 
experiments in the 1920s (29). The first use of randomization 
in medical experimentation occurred in the 1930s and the 
first multicenter controlled clinical trials began in the 1940s. 
The importance ofclinical trials was increased after amend- 
ments to the charter of the Food and Drug Administration in 
1962 required that drug approval be based on evidence from 
controlled investigations (29). Because of the rigor of the 
experimental design, randomized controiled clinical trials 
have had particular impact on therapeutic decision making. 
A selected number of major clinical trials in cardiovascular 
disease are listed in Table 2 (30-78). 
Clinical impact., The impact of a randomized clinical trial 
is greatest when it can establish a broad therapeutic princi- 
ple. For example, the lipid hypothesis of coronary athero- 
sclerosis was based on pathologic observations of coronary 
art!:ne;, as well as consistent epidemiologic evidence linking 
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serum cholesterol tocoronary heart disease. Nevertheless, 
pathOphySiOlOgic reasoning and statistical aSSOCiatiOnS Of 
elevated serum cholesterol with coronary disease did not 
constitute convincing proof of the hypothesis that lowering 
serum cholesterol would reduce coronary heart disease. The 
Lipid Research Clinics Primary Prevention Trial (3O,31) was 
designed to test the lipid hypothesis directly, The Primary 
Prevention Trial used cholestyramine to treat men aged 35 to 
59 years with serum cholesterol levels of 265 mgldl or 
greater, This study demonstrated a significant 19% reduction 
in coronary heart disease nd points (coronary death or 
nonfatal myocardial infarction) over 7 years Of follow-up 
(30). Evidence from this trial has been considered tobe the 
“keystone” joining evidence from basic sciences, epidemi- 
ology and clinical investigation to establish t e lipid hypoth- 
esis. 
Controversial aspects ofclinical triads. Some of the con- 
troversy regarding clinical trials relates to the question of 
whether a trial should be subject to “narrow interpretation” 
or “broad interpretation.” The controversy over the Lipid 
Research Clinics Primary Prevention Trial is less over the 
validity of the findings in the subjects randomized than over 
whether those findings can be generalized to other groups of 
patients. A very narrow interpretation would be that only 
patients imilar to those enrolled in the trial (middle-aged 
men) with cholesterol elevated tosimilar levels (>265 mg/dl) 
and treated with the same drug (cholestyramine) would 
receive benefit. The trial has received the broader interpre- 
tation that lowering cholesterol leads to reduction i  coro- 
nary heart disease mortality. This interpretation relies on 
additional evidence to lead to the more xtensive r commen- 
dations regarding cholesterol lowering that have now been 
promulgated aspart of the National Cholesterol Education 
Program (79). 
In a strict sense, the results of a randomized trial apply 
only to the patients who were enrolled, or perhaps to 
patients meeting the study entry criteria and given the 
identical treatment. I  is a “leap of faith” to expand the 
results of a trial into a broad therapeutic principle, Trial 
evidence has been used to establish widely accepted princi- 
ples regarding treatment ofmild hypertension, thrombolytic 
therapy for acute myocardial infarction and beta-blocker use 
after myocardial infarction. 
It is simpler to demonstrate that a therapy works for some 
Patients than it is to define precisely the population that 
benefits. The number of patients that must be enrolled in a 
trial becomes much greater as lower risk patients are in- 
cluded. Trials of mild disease are therefore more difficult to 
conduct and may not be practical. Because a randomized 
trial will not be done for every subgroup, the extrapolation f 
trials conducted inseverely diseased patients to treatment of 
less severely affected patients will always be an issue for 
debate. 
Table 3. Major Data Bases in Cardiovascular Disease 
Duke Cardiovascular Disease Databank (20,81-93) 
Seattle Heart Watch (94-97) 
Coronary Artery Surgery Study Registry (98-106) 
NHLBI PTCA Registry (107-113) 
Catheter Ablation Registry (114) 
Valvuloplasty Registry 
8 
chcd trial is the 
best method for testing therapeutic ~ypot~cses, it is 
difficult, expensive and time-consuming exercise. The 
Research Clinics Primary Prevent Triai, for instance, 
lasted 15 years and cost $142,250 . In an era of fiscal 
limits, the ability to plan and fund 1 linical trials is much 
less than in the 1960s and 1970s. It is simply 
perform randomized studies to answer every 
result, there is considerable interest in targe 
trials to the topics most likely to require this definitive form 
of study and in developing alternatives to
randomized controlled clinical trial. The use 
bases and registries to address the 
provide a complementary pproach 
(go). 
Modern observational data bases hare many method- 
ologic strengths with randomized studies, including standard 
definitions for data, complete and prospective data collec- 
tion, use of computerized data management, comprehensive 
patient follow-up and multidisciplinary research teams (80). 
ExampIes of modern data bases are provided in Table 3 (20, 
of o~e~a~io~ 
Although there is little doubt hat o 
can characterize tr nds in management a d patient outcome 
and identify prognostic factors, it remains controversial 
whether they can be used to evaluate herapy (80). Our view 
is that observational data bases can and should play an 
important role in the evaluation oftherapy. By design, adata 
base is relatively nonselective, sothat he entire spectrum of
patients with disease isrepresented. Many patients included 
in a clinical data base would not be included in a randomized 
trial. In the Coronary Artery Surgery Study, for instance, 
only 13% of patients met all eligibility criteria for random- 
ization (53), and only 4.2% of patients in the Duke Cardio- 
vascular Disease Databank met hese same ligibili 
(115). The broad spectrum of patients in a clinical 
permits analysis of subgroups excluded from or poorly 
represented in randomized stud&. A number of observa- 
tional studies have been published from the registry of the 
Coronary Artery Surgery Study that bave considerably 
enhanced the value of the overall investigation, i cluding 
examinations of the efficacy of coronary bypass urgery in 
of the number of factors 
groups from the Veterans 
pean Cooperative Su 
Sorgery study (115). 
randomized trials in assisting cli~ica9 decision 
whether a99 patients enro99e 
esults are often rep d separately for several 
~~servati~~s sMggest that t 
susgery on survival should b 
Advances in therapeutic decision making will depend on 
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Table 4. Selected Ongoing Trials in Cardiovascular Disease 
coronnry PnpJoPlDsty 
Bypass Angioplasty Revascularization Investigation (BARD 
Emory Angioplasty Surgery Trial (EAST) 
Randomized Interventional Treatment of Angina (RITA) 
German Angioplasty Bypass Interventional Trial (GABI) 
Coronary Angioplasty Bypass Revascularization Investigation (CABRI) 
Angioplasty Compared to Medicine (ACME) 
Thmmbdysis far acute Is&en& qndmmes 
Gruppo Italiano per lo Studio della Supravivenza nell’ Infarct0 
Miocardico (GISSI-2) 
International Study of Infarct Survival, Phase 3 (ISIS-3) 
Thrombolysis and Angioplasty in Myocardial Infarction Studies 
(TAM14 TAM14 
Thrombolysis in Myocardial Infarction Study, Phase 3 (TIMI-3) 
Late Assessment of Thrombolytic ElBcacy (LATE) 
Estudio Multicentrico Estreptoquinasa Republica Argentina (EMERA) 
Iwe-shm 
Systolic Hypertension in the Elderly (SHEP) 
Atheroselerosb 
Stanford Coronary Risk Intervention Project (SCRIP) 
Post Coronary Artery Bypass Graft Study 
Program on Surgical Control of Hyperlipidemias (POCOSH) 
Congestive heart failure 
Studies of Left Ventricular Dysfunction (SOLVD) 
Survival and Ventricular Enlargement (SAVE) 
Immunosuppressive Therapy for Biopsy Proven Myocarditis 
Arrltythmlas 
Cardiac Arrhytltmia Suppression Trial (CAST) 
Electrophysiologic Study versus Electrocardiographic Monitoring for 
Selection of Antiarrhythmic Therapy of Ventricular 
Tachyarrhythmias (ESVEM) 
cal observations and epidemiologic analyses will also be 
essential sources of the insights needed to advance both 
therapeutics and clinical decision making. 
There are a number of major clinical trials underway or 
being planned that will expand the knowledge base for 
clinical decision making (Table 4). The treatment of acute 
myocardial infarction is under intensive investigation, and 
the array of clinical t&s should provide large amounts of 
data. Six trials of coronary angioplasty are also underway or 
in the planning stages. These studies will be completed 
between 1989 and the mid 199Os, and should provide data fur 
decision making into the 21st century. 
Multicenter studies. One development that has enhanced 
the conduct of randomized trials is the emergence of rela- 
tively stable multicenter collaborative groups that perform a
series of studies. This model for clinical trials has long been 
used by cancer investigators, in part because no one clinical 
center treated enough patients with particular forms of 
cancer to perform therapeutic studies. With the increased 
recognition fthe need for large sample sizes, as well as the 
need for timely data to address pressing cilinica 
the value of stable multicenter coliaborative arra 
becoming recognized by cardiovascular investi 
major advantages of ongoing collaborations 
establishment of a communications i frastructure, i~c~~~~~~g 
standardization f methods, terminology and procedures, 
need not be repeated for each study, and that the talented 
interdisciplinary team necessary for such trials can be main- 
tained intact. 
from a variety of sources to arrive management strategies. 
Published studies vary in design, ality, accessibility and 
impact. Reviews by experts can e findings from dispa- 
rate studies within a conceptual framework for consistent 
interpretation, but such reviews rely heavily o
er’s judgment to weigh evidence from distinct st 
priately (I 17-119). 
The technique of meta analysis has been increasingly 
applied in recent years. Meta analysis was o~gi~al~y devel- 
oped in the social sciences (120,121), and achieved promi- 
nence in the medical literature in 1977 when Chalmers et al. 
(122) pooled the results of several small randomized trials of 
anticoagulant therapy for acute myocardial infarction. Al- 
though the legitimacy of the technique has been challenged 
(118,120,123,124), meta analysis has been 
plied to cardiovascular disease (125,126). 
have been published combining data from 
in acute myocardial infarction of thrombolytic therapy 
(127,128), beta-adrenergic blockade (129), lidocaine (130) 
and nitrates (131J, as well as trials of secondary prevention 
after myocardial inf+rction using antiarrhythmic agents 
(132), beta-blockers (1,29,132), aspirin (133), anticoagulant 
agents (122,132) and exercise training (132,134). Other meta 
analyses have examined treatment ofcongestive heart fail- 
ure (135,136) and hypertension (137,138). A summary of 
meta analytic results in cardiovascu”iar disease has been 
recently published (~25,126). 
Possible limitations. The techniques of meta analysis 
have been criticized on a variety of grounds (120,123,124). 
Although seemingly simple to perform, meta analysis is a 
fairly demanding and complex technique. The quality of 
meta analyses varies considerably (121), and several inter- 
ested investigators (117,121) have proposed method 
standards toensure the technical quality of analysis. 
ever, philosophical issues regarding meta nalysis cannot be 
resolved as simply. Many observers emain concerned about 
the heterogeneity among studies in terms of patient charac- 
teristics, treatments, regimens an 
Should more weight be given to “good” studies? Does a 
meta analysis of small studies eliminate the need for a large 
al, these data bases 
data bases ~ac~~de informat 
patients, and provide a ~~~q~e 
therapy as provided in the co 
data from clinical trials and obs 
ending specific ther 
‘ideal” results and 
may alter thera~e~t~c reco 
Gents, as well as 
icare data ior exa 
oronary revascu- 
z&ions in seven 
states. The ext 
cfiveness of digress therapies for 
able research will be nec- 
which are not available inclaims data bases (146). 
posed to the experience of academic medical centers on 
highly selected patient populations. 
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Clinical data bases will likely become increasingly more 
important means of providing data for clinical decision 
making. A clinical data base can provide valuable informa- 
tion to individual physician& about he delivery of care at 
their hospital and allow extrapolation f pub”lished informa- 
tion from clinical trials or observational studies. 
computer-aided decision makiig. Several trends are driv- 
ing the deve!opment of clinicai data bases. Dramatic in- 
creases in microcomputer capabilities coupled with decreas- 
ing costs now make clinical data bases financially feasible for 
even small practices. Physicians are becoming more com- 
puter literate as newly trained physicians enter practice and 
established physicians “retrain” themselves. Increasing 
medical costs have put enormous pressure on physicians to 
account for the quality and cost of care provided. Increased 
paperwork will require efficient methods for information 
management. The practice of medicine has become more 
competitive, ncouraging physicians and hospital adminis- 
trators to “market” their services. There is a growing body 
of evidence to suggest that computer-aided decision making 
is superior to more traditional approaches (147-150). In
response to these trends, it seems inevitable that local data 
bases will continue to proliferate. 
ve data bases. These can be developed 
to from a variety of practice settings in 
geographically dispersed areas. Such data bases could pro- 
vide information more representative of clinical practice 
than current data bases from individual hospitals that have 
relatively homogeneous practice patterns. To realize the 
potential for collaborative clinical data bases, a number of 
problems must be overcome (151). Before information from 
a number of diverse practice settings can be shared to 
perform observational research studies, acommon terminol- 
ogy must be developed, as well as similar approaches for 
collecting and ensuring the quality of data. New biostatisti- 
Cal methods must be developed to analyze the increasingly 
more complex practice of cardiology. A sound financial base 
is required for the installation and maintenance of a collab- 
orative data base for it to be feasible to collect long-term 
outcome information. Financial support will likely be real- 
ized not only from the physician, but also from hospital 
administrators. Consequently, the implementation strategy, 
focus and function of the data base will need to meet a 
variety of objectives. Successful development of huge scale 
collaborative clinical data bases will require considerable 
input and communication among all parties with a stake in 
their development-the physician, hospital administrator, 
planner and researcher. 
ehhallenges. It is unlikely that the 
potential of clinical data bases to improve the practice of 
medicine will be realized without he physician playing a 
Prominent role in their development. The challenge to the 
cardiologist practicing in the 1990s is to recogn 
fundamental changes in the practice nvironment 
opportunities toimprove the quality of care. Physic 
need to understand how to use computers to practice more 
efficiently and to support he development of clinical data 
bases that not only will allow others to monitor the quality 
and cost of care provided, but also will enable physicians to 
improve the quality of care. 
Physicians will continue to face cult decisions about 
choice of therapy, but there will be better in ation in the 
future to guide such decisions. There will number of 
randomized controlled clinical trials, new data base tech- 
niques, and, most irn~o~a~t~y~ new pathop 
sights from both basic research and keen clinical observa- 
tions that will create paradigms for therapy. 
We thank Thomas Robertson, MD and Eric Topol, MD for information 
concerning ongoing trials, and Alexandria Lubans and Melissa Hurt for 
assistance in preparing the manuscript. 
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